Hyperbilirubinemia and neurologic signs in dogs with non-associative immune-mediated hemolytic anemia: 81 cases (2015–2024)

Sasha Chapman, John M. Angles, Christine Griebsch, Jane A. YuJournal of Veterinary Internal Medicine 2026 · DOI

TL;DR

This study investigates the link between high bilirubin levels and neurological signs in dogs with immune-mediated hemolytic anemia (IMHA). It found a strong association, suggesting that monitoring bilirubin is crucial for early detection and intervention of potential neurological complications, even if bilirubin isn't the sole cause.

What Problem Does This Paper Address?

Immune-mediated hemolytic anemia (IMHA) is a serious condition in dogs where their immune system attacks red blood cells. A known complication of IMHA is hyperbilirubinemia (high bilirubin levels) due to the breakdown of red blood cells. While bilirubin encephalopathy (brain dysfunction caused by bilirubin) is recognized in humans, it's considered rare and poorly understood in dogs. This paper aims to clarify the relationship between elevated bilirubin and neurological signs in dogs with IMHA, specifically looking for thresholds that might predict these signs and improve clinical management.

Methods

This was a retrospective, multi-center cohort study involving 81 dogs diagnosed with non-associative IMHA and hyperbilirubinemia. Researchers collected data on signalment, clinical signs, clinicopathological data, treatment, and outcomes. Key to their analysis was the serial measurement of bilirubin concentrations at baseline, peak, initial decrease, and normalization. They used univariable logistic regression to assess the association between neurologic signs and various factors, including bilirubin levels. Receiver operating characteristic (ROC) curves were employed to identify optimal bilirubin cut-off values for predicting neurologic signs.

Datasets

The study utilized medical records from 8 veterinary referral institutions across Australia, spanning cases from January 2015 to December 2024. The dataset comprised 81 dogs meeting specific inclusion criteria for IMHA and hyperbilirubinemia. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • Bilirubin as a Warning Sign: The study strongly suggests that high bilirubin levels, particularly at baseline and peak, are significant predictors of neurological signs in dogs with IMHA. This elevates bilirubin monitoring from a general indicator of IMHA severity to a more specific tool for anticipating neurological issues.
  • Thresholds for Concern: Identifying specific bilirubin concentration thresholds (e.g., ≥3.3 mg/dL at baseline, ≥13.9 mg/dL at peak) that dramatically increase the odds of neurological signs is a critical takeaway. This provides clinicians with actionable targets for increased vigilance.
  • Beyond Bilirubin: While bilirubin is a key factor, the study acknowledges that it's likely not the sole cause of neurological signs. Other contributing factors like systemic inflammation, hypercoagulability, and anemia-related ischemia are also implicated, highlighting the complex nature of IMHA's neurological impact.
  • Time to Peak Matters: Interestingly, dogs taking longer to reach their peak bilirubin concentration had a higher likelihood of developing neurological signs. This contrasts with human findings and suggests a potential role for chronic exposure or a different disease progression in dogs.

Key Results

  • Prevalence of Neurologic Signs: 20% (16 out of 81) of the dogs developed neurological signs, which included stupor, non-ambulatory tetraparesis, and generalized seizures.
  • Strong Bilirubin Association: A significant association was found between neurologic signs and both baseline and peak bilirubin concentrations (P < .001).
  • Odds Ratios: Dogs with baseline bilirubin ≥3.3 mg/dL had 12.2 times higher odds of developing neurologic signs. This jumped to a staggering 93.3 times higher odds for dogs with peak bilirubin ≥13.9 mg/dL.
  • Other Risk Factors: Dogs taking ≥2 days to reach peak bilirubin and those aged ≥7 years also had increased odds of developing neurologic signs. Higher BUN concentrations were also associated with a greater likelihood of neurological signs.
  • Outcome: Dogs with neurologic signs had a lower survival rate (31% survived) compared to those without (81% survived).

Limitations and Future Work

  • Retrospective Design: The study's retrospective nature limits the ability to establish definitive causation and means that not all diagnostic tests (like advanced brain imaging) were performed consistently.
  • ABE Diagnosis: Diagnosing acute bilirubin encephalopathy (ABE) in dogs is challenging due to a lack of established criteria and neuroimaging findings. The study relied on clinical assessment and exclusion of other causes.
  • Confounding Factors: The study acknowledges that other factors, such as systemic inflammation, hypercoagulability, and anemia, likely contribute to neurological signs, and bilirubin may not be the sole driver.
  • Generalizability: The identified bilirubin cut-offs are specific to this study cohort and may not be universally applicable to all dogs with IMHA.
  • Future Work: The authors suggest that future prospective studies are needed to evaluate the efficacy of therapeutic interventions, such as therapeutic plasma exchange (TPE), for managing severe IMHA with hyperbilirubinemia and neurologic signs. Long-term outcome studies are also recommended.

Summary updated

Abstract

Although the causation of the neurologic signs cannot be attributed solely to bilirubin based on our study, these findings emphasize the importance of monitoring serum bilirubin concentrations and the development of neurologic signs in dogs with IMHA. The results reflect findings in our study population and may not be directly applicable to all dogs with IMHA.
BibTeX
@article{chapman2026hyperbilirubinemia,
  author = {Sasha Chapman and John M. Angles and Christine Griebsch and Jane A. Yu},
  title = {{Hyperbilirubinemia and neurologic signs in dogs with non-associative immune-mediated hemolytic anemia: 81 cases (2015–2024)}},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  doi = {10.1093/jvimsj/aalaf034},
}
Figure